Skip to main content

Table 3 Summary of study characteristics and costs per DALY averted for interventions targeting children

From: Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review

References

Publication year

Country/region

Malaria intervention

Main data sources

Life tables source

Cost-effectiveness threshold used

Cost-effectiveness ratio (cost per DALY averted)

DALYs averted per $ 1 million spent on intervention

[1]

2000

Tanzania

Chemoprophylaxis

Clinical trial

Passive case detection

Survey

Model life table West 25 and 26

US$30–US$ 150

$11–12

86,956

[2]

2008

Togo

LLITNs

Regional estimates

Financial records and interviews

Togo life tables

US$30–US$ 150

$16.39

61,013

[3]

2009

Mozambique and Tanzania

Intermittent preventive treatment in infants (IPTi)

Expanded program on immunization

East African life table

US$ 30 and US$ 150

$3.70 in Tanzania

270,270

$11.20 in Mozambique

89,286

[4]

2010

Multi-country

Intermittent preventive

Treatment (ITP)

Model

Country-specific

US$ 202

$2.90–$39.63

47,170

[5]

2010

 

Pre-referral rectal artenusate

 

Sub-Saharan Africa life table

1–3 times GDP per capita

I$77c (at full uptake)

12,987

[6]

2011

Multi-country (Tanzania, Uganda, Nigeria)

Parenteral artenusate

Clinical trials

Country-specific (3 countries)

US$30–US$ 150

$123a

8130

[7]

2011

Model

Intermittent

preventive treatment in infants (IPTi) and children (IPTc)

Simulation model

Clinical trials

East African life table

US$ 37–US$223

<$100

<10,000

[8]

2014

Africa

Dihydroartemisinin–piperaquine (DP) and artemether–lumefantrine (AL)

Randomised trials

WHO African sub-region life table

Not stated

$0.96 per child over one yearb

Not applicable

[9]

2014

Malawi

Vaccines and Lon lasting insecticide treated nets (LLITNs)

Published sources

Malawian life table

1–3 times GDP per capita

$145.03 (from a health service perspective

6895

[10]

2014

Tanzania

Dihydroartemisinin–piperaquine

Artemether–lumefantrine

Published studies

Health facility

Tanzanian life table

US$ 30–US$ 150

GDP per capita

$12.40–12.54

80,192

  1. aThese were DALYs averted after treatment with artenusate compared to quinine as a baseline
  2. bFirst-line treatment with dihydroartemisinin–piperaquine (DP) compared to artemether–lumefantrine saved $0.96
  3. cI$ stands for international dollars